Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 16/20 | 0.66 |
| ▸ | FNTB | P49356 | 16/20 | 0.66 |
| ▸ | PGGT1B | P53609 | 4/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | RORC | P51449 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13333614 | 1.00 | FNTA (0.66) | FNTAFNTBPGGT1BCYP3A4RORC | |
| SCHEMBL13333685 | 0.89 | FNTA (0.64) | FNTAFNTBPGGT1BCYP3A4RORC | |
| SCHEMBL6010415 | 0.86 | RORC (0.58) | FNTAFNTBRORC | |
| SCHEMBL6174296 | 0.82 | RORC (0.51) | FNTAFNTBRORC | |
| SCHEMBL13752025 | 0.81 | FNTA (0.48) | FNTAFNTBPGGT1BCYP3A4RORC | |
| SCHEMBL6171298 | 0.81 | RORC (0.57) | FNTAFNTBRORC | |
| SCHEMBL6169851 | 0.81 | RORC (0.51) | FNTAFNTBRORC | |
| SCHEMBL6170022 | 0.81 | RORC (0.54) | FNTAFNTBRORC | |
| SCHEMBL6010179 | 0.81 | RORC (0.52) | FNTAFNTBRORC | |
| SCHEMBL6171742 | 0.81 | RORC (0.54) | FNTAFNTBRORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1756085-B1 | DIASTEREOSELECTIVE SYNTHESIS PROCESS WITH 6-BROMO-4-(3-CHLOROPHENYL)-2-METHOXY-QUINOLINE | JANSSEN PHARMACEUTICA NV (BE) | 2010-06-16 | — | — | EP | disclosed |
| EP-1756085-B1 | DIASTEREOSELECTIVE SYNTHESIS PROCESS WITH 6-BROMO-4-(3-CHLOROPHENYL)-2-METHOXY-QUINOLINE | JANSSEN PHARMACEUTICA NV (BE) | 2010-06-16 | — | — | EP | disclosed |
| US-7572916-B2 | Diastereoselective synthesis process with 6-bromo-4-(3-chlorophenyl)-2-methoxy-quinoline | JANSSEN PHARMACEUTICA NV (BE) | 2009-08-11 | — | — | US | disclosed |
| US-7572916-B2 | Diastereoselective synthesis process with 6-bromo-4-(3-chlorophenyl)-2-methoxy-quinoline | JANSSEN PHARMACEUTICA NV (BE) | 2009-08-11 | — | — | US | disclosed |
| US-7572916-B2 | Diastereoselective synthesis process with 6-bromo-4-(3-chlorophenyl)-2-methoxy-quinoline | JANSSEN PHARMACEUTICA NV (BE) | 2009-08-11 | — | — | US | disclosed |
| US-20070293680-A1 | For the preparation of (R)-(+)-6-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl) methyl]-4-(3-chlorophenyl)-1-methyl2(1H)-quinolinone; farnesyl tranferase inhibitory activity | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-12-20 | — | — | US | disclosed |
| US-20070293680-A1 | For the preparation of (R)-(+)-6-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl) methyl]-4-(3-chlorophenyl)-1-methyl2(1H)-quinolinone; farnesyl tranferase inhibitory activity | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-12-20 | — | — | US | disclosed |
| US-20070293680-A1 | For the preparation of (R)-(+)-6-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl) methyl]-4-(3-chlorophenyl)-1-methyl2(1H)-quinolinone; farnesyl tranferase inhibitory activity | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293680-A1 | For the preparation of (R)-(+)-6-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl) methyl]-4-(3-chlorophenyl)-1-methyl2(1H)-quinolinone; farnesyl tranferase inhibitory activity | FNTB, CYP4F2, FNTA | FNTA 3/4885FNTB 1/4885PGGT1B 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.